cabazitaxel (Jevtana)

following a second resubmission assessed under the end of life process

cabazitaxel (Jevtana®) is accepted for restricted use within NHS Scotland.

Indication review: cabazitaxel in combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

SMC restriction: for use in patients who have received at least 225mg/m2 (three cycles) of docetaxel and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

In an open-label, multicentre, randomised-controlled, phase III study in patients with metastatic hormone refractory prostate cancer, treatment with cabazitaxel plus prednisone/prednisolone was associated with an extended median overall survival of 2.4 months compared with an alternative chemotherapy regimen. 

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of cabazitaxel. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.